DOI: 10.1002/pbc.28946
View full text
Maureen M. O'Brien, Todd A. Alonzo, Todd M. Cooper, John E. Levine, Patrick A. Brown, Tamra Slone, Keith J. August, Bouchra Benettaib, Noha Biserna, Jennifer Poon, Meera Patturajan, Nianhang Chen, Mathew Simcock, Linda Zimmerman et al.

Abstract: Background: Outcomes after relapse remain poor in pediatric patients with acute myeloid leukemia (AML), and new therapeutic approaches are needed. Lenalidomide has demonstrated activity in adults with lower risk myelodysplastic syndromes and older adults with relapsed or refractory (R/R) AML. Methods:In this phase 2 study (NCT02538965), pediatric patients with R/R AML who received two or more prior therapies were treated with lenalidomide (starting dose 2 mg/kg/day on days 1-21 of each 28-day cycle) for a maxi…

expand abstract